How do I Apply for a CEP? An Updated Guideline of the EDQM Provides Information
Many companies have already started to submit their authorisation applications electronically. With regard to a centralised marketing authorisation, this has been the only way for some time. For a Certificate of Suitability (CEP) application both ways can still be used, though: sending in paper form or electronic transmission.
The EDQM recently published an updated guidance entitled "Guidance for electronic and paper submissions for certificates of suitability (CEPs) applications". This document describes in detail the use of different formats for the submission and the respective procedure. The following formats are accepted:
•eCTD — This is the format that is used for the electronic submission of authorisation applications. However, the guideline points out that from a technical perspective it remains a 'standalone' dossier, which is distinct from any marketing authorisation eCTD dossier and life cycle. Furthermore, it is recommended to validate the eCTD technically prior to submission to the EDQM (using validation checker tools). If error messages appear during the validation by the EDQM, the submission is blocked or rejected, which delays the whole process of submission. The EDQM recommends the use of this format.
•NeeS — The "non eCTD electronic submission" (NeeS) uses a format different from the CTD. Structure and specification of the format must meet the requirements described in the guidance document of the "EU telematics implementation group for electronic submissions" (TIGes) with the title "TIGes harmonised guidance for non eCTD electronic submissions (NeeS) for human medicinal products in the EU".
•PDF — In this format, the modules 1–3 have to be listed separately. The use of bookmarks is recommended.
To better structure the extensive information additional sections can be introduced in all three formats (extension of granularity). When submitting these documents in paper form, they are initially scanned by the EDQM and then destroyed. Due to this process there can be a delay depending on the volume of the documentation, because the clock-start for the dossier begins only after this process is complete.
Basically, switching from paper to electronic submission is possible and recommended by the EDQM. However, once a company opted for the electronic way, going back to paper dossier is impossible.
The guideline contains 6 Annexes, describing the directory and folder structure of the formats and the granularity levels in more details. Annex 6 is particularly useful as it lists the most common mistakes that may lead to a blocking of the application process.
Related News
-
News PSCI Welcomes Delpharm, Samsung Biologics, and Suven as First Supplier Partners
The pharmaceutical industry continues to evolve with an increasing focus on responsible sourcing, sustainability, and collaboration across the supply chain. Under a new model to recognise suppliers within the pharmaceutical and healthcare industry that... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Eli Lilly's weight loss drugs removed from the FDA's shortage list
The US FDA have recently updated their drug shortage list. The recently released list shows that all dosage forms of Eli Lilly's weight-loss drug Zepbound and their diabetes drug Mounjaro are now available. -
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance